A
Angelo Balestrieri
Researcher at University of Cagliari
Publications - 44
Citations - 2951
Angelo Balestrieri is an academic researcher from University of Cagliari. The author has contributed to research in topics: Hepatitis B virus & Hepatitis. The author has an hindex of 18, co-authored 44 publications receiving 2848 citations.
Papers
More filters
Journal ArticleDOI
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.
Patrizia Farci,Atsushi Shimoda,Alessandra Coiana,Giacomo Diaz,Giovanna Peddis,Jacqueline C. Melpolder,Antonello Strazzera,David Y. Chien,Santiago J. Munoz,Angelo Balestrieri,Robert H. Purcell,Harvey J. Alter +11 more
TL;DR: Sequences within the HCV E1 and E2 envelope genes were analyzed during the acute phase of hepatitis C in 12 patients with different clinical outcomes to indicate that the evolutionary dynamics of theHCV quasispecies during the emergency phase predict whether the infection will resolve or become chronic.
Journal ArticleDOI
The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey.
Fabrizio Aghini-Lombardi,L Antonangeli,Enio Martino,Paolo Vitti,Maccherini D,Francesco Leoli,Teresa Rago,Lucia Grasso,Rocco Valeriano,Angelo Balestrieri,Aldo Pinchera +10 more
TL;DR: In the present survey of an iodine-deficient community, a progressive increase with age of goiter prevalence, thyroid nodularity, and functional autonomy was observed, twice as high as that reported in iodine-sufficient areas, mainly due to an increased frequency of toxic nodular goiter.
Journal ArticleDOI
Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children
Me Lai,Anna Paola Mazzoleni,Angelo Balestrieri,F Argiolu,S. De Virgilis,Antonio Cao,Robert H. Purcell,Patrizia Farci +7 more
TL;DR: HCV infection may not induce protective immunity, which has implications for vaccine development and is investigated in three polytransfused thalassaemic children.
Journal ArticleDOI
Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis
Patrizia Farci,Tania Roskams,Luchino Chessa,Giovanna Peddis,Anna Paola Mazzoleni,Rosetta Scioscia,Giancarlo Serra,Maria Eliana Lai,M Loy,L. Caruso,Valeer Desmet,Robert H. Purcell,Angelo Balestrieri +12 more
TL;DR: High doses of interferon alpha-2a significantly improved the long-term clinical outcome and survival of patients with chronic hepatitis D, even though the majority had active cirrhosis before the onset of therapy.
Journal ArticleDOI
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.
Patrizia Farci,R Strazzera,Harvey J. Alter,Stefania Farci,Daniela Degioannis,Alessandra Coiana,Giovanna Peddis,Francesco Usai,Giancarlo Serra,Luchino Chessa,Giacomo Diaz,Angelo Balestrieri,Robert H. Purcell +12 more
TL;DR: The study of the evolution of the HCV quasispecies provides prognostic information as early as the first 2 weeks after starting therapy and opens perspectives for elucidating the mechanisms of treatment failure in chronic hepatitis C.